NASDAQ · SGHT
Healthcare · Medical - Devices
$8.14
Down-$0.16 (-1.93%)
Updated Sep 17, 2026, 5:13 PM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
SGHT closed at $8.08 after 20 trading sessions, down 0.86% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 17, 2026 | $8.32 | $8.32 | $7.97 | $8.08 | 201.33K |
| Sep 16, 2026 | $8.18 | $8.355 | $7.99 | $8.14 | 168.28K |
| Sep 15, 2026 | $8.11 | $8.22 | $7.95 | $8.11 | 88.8K |
| Sep 14, 2026 | $8.10 | $8.21 | $8.0701 | $8.13 | 120.72K |
| Sep 11, 2026 | $8.13 | $8.315 | $7.9917 | $8.14 | 179.56K |
| Sep 10, 2026 | $7.93 | $8.095 | $7.70 | $8.005 | 167.81K |
| Sep 9, 2026 | $8.01 | $8.24 | $7.90 | $8.05 | 167.16K |
| Sep 8, 2026 | $8.36 | $8.37 | $8.06 | $8.10 | 166.95K |
| Sep 4, 2026 | $8.27 | $8.45 | $8.14 | $8.35 | 102.47K |
| Sep 3, 2026 | $8.50 | $8.64 | $8.31 | $8.38 | 93.64K |
| Sep 2, 2026 | $8.02 | $8.79 | $7.822 | $8.42 | 269.38K |
| Sep 1, 2026 | $8.39 | $8.53 | $8.18 | $8.19 | 133.42K |
| Aug 31, 2026 | $8.54 | $8.57 | $8.30 | $8.50 | 205.49K |
| Aug 28, 2026 | $8.35 | $8.55 | $8.32 | $8.55 | 118.82K |
| Aug 27, 2026 | $8.30 | $8.548 | $8.25 | $8.41 | 165.31K |
| Aug 26, 2026 | $8.30 | $8.435 | $8.18 | $8.37 | 117.67K |
| Aug 25, 2026 | $8.37 | $8.42 | $8.205 | $8.32 | 125.84K |
| Aug 24, 2026 | $8.23 | $8.50 | $8.20 | $8.38 | 169.68K |
| Aug 21, 2026 | $8.25 | $8.35 | $8.05 | $8.26 | 180.59K |
| Aug 20, 2026 | $8.36 | $8.448 | $8.13 | $8.15 | 162.76K |
The latest Smart Investors Daily articles mentioning SGHT.
SGHT research
Company profile and research snapshot.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 6, 2026 | UBS | Buy | — |
| Jul 8, 2026 | Citigroup | Neutral | — |
| May 28, 2026 | Citigroup | Neutral | — |
| Mar 6, 2026 | Citigroup | Neutral | — |
| Mar 6, 2026 | UBS | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 19, 2026
Indications for Use state:"The Sight Sciences TearCare System is a thermal-activated gland expression therapy that improves meibomian gland function in adult patients with evaporative dry eye disease due to
Benzinga · Mar 6, 2026
Citigroup analyst Joanne Wuensch maintains Sight Sciences (NASDAQ:SGHT) with a Neutral and lowers the price target from $9.1 to $6.5.
Benzinga · Mar 5, 2026
ChartMill · Mar 4, 2026
Sight Sciences reports mixed Q4 2025 results, beating EPS estimates but slightly missing revenue forecasts. The company also issued its 2026 financial guidance.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SGHT.
